Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

5 Customer Reviews

  • Tumors were resected from mice 10 days after orthotopic inoculation of 4T1-Luc2 cells, and hydrogels loaded with the following payloads were evaluated: anti–PD-1, anti-CTLA-4, IL-15sa, lenalidomide, celecoxib, STING-RR, or R848. Mice that did not receive a hydrogel were examined as a negative control. (A) IVIS imaging of 4T1-Luc2 cells is shown for all groups described and illustrates tumor burden.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Celecoxib purchased from Selleck.

    Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

  • Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

    Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

  • Oncol Lett, 2018, 16(1):317-325. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MV;GeY5kfGmxbjDBd5NigQ>? M3LNXVAvOS1|MDFOwG0> NVK0Z3BlPDhiaB?= MmnybY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> MmDqNlY2OTNzN{K=
H460 NHnqOVFHfW6ldHnvckBCe3OjeR?= M3qwSVAvOS1|MDFOwG0> MYC0PEBp MYjpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> MXyyOlUyOzF5Mh?=
HKESC-2 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[w[ZMzOMLizszN MmnGOFjDqGkEoB?= NVTJU41Oe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi MnzBNlY1PzR4OUO=
CaES-17 NEjhWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Kwe|IxyqEQvF2= M4n4VFQ5yqCqwrC= MVfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> MV2yOlQ4PDZ7Mx?=
HKESC-2 NUXS[XE5SXCxcITvd4l{KEG|c3H5 MlnkNlDDqM7:TR?= NGPkTWw1QMLiaNMg Mn;KdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MVWyOlQ4PDZ7Mx?=
CaES-17 MWnBdI9xfG:|aYOgRZN{[Xl? NWTSclhmOjEEoN88US=> MXe0POKhcMLi M3rudJJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MViyOlQ4PDZ7Mx?=
A549 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13MO|UuOTZyIN88US=> MlSzOFjDqGkEoB?= NFyzSYVFVVOR M4DF[mlEPTB;MU[zMlQh|ryP MoLiNlY1PjR4NEO=
HCC827 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[1MVE3OCEQvF2= MXS0POKhcMLi M4PIN2ROW09? NUT2V5l3UUN3ME22PU4zKM7:TR?= NYLYboM6OjZ2NkS2OFM>
A549 M4nxVmFxd3C2b4Ppd{BCe3OjeR?= M2e0PFgxKML3TR?= NIjKeW41QMLiaNMg M4jNN2ROW09? NED0cW5qdmS3Y3XzJIFxd3C2b4Ppdy=> NH3OTWIzPjR4NE[0Ny=>
HCC827 NYD5VnlCSXCxcITvd4l{KEG|c3H5 NV7COGkzQDBiwsXN NEjV[5Q1QMLiaNMg NHHXcJJFVVOR NH;EOFhqdmS3Y3XzJIFxd3C2b4Ppdy=> M4DSUlI3PDZ2NkSz
SGC-7901/DDP M1PTTmZ2dmO2aX;uJGF{e2G7 MlruNVDDqML3TR?= NHTBVFkzPCCq MmHUbY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW|c3nvci=> NWDlNnkxOjZ2MEe2OVM>
SGC-7901  NYDMTnlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLjbVA3OjUEoHlCpC=> M4LKfGlEPTB;MUG1MlA5KM7:TR?= NITQT5UzPjRyN{[1Ny=>
SGC-7901/DDP MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHQNlTDqGkEoB?= NEfv[WRKSzVyPUO1MlQ2KM7:TR?= M3fvOlI3PDB5NkWz
SGC-7901/DDP MXnBdI9xfG:|aYOgRZN{[Xl? MmO0NVDDqML3TR?= MXGyOEBp Mn\2bY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> NXnafG13OjZ2MEe2OVM>
SGC-7901/DDP NVPKXVg6TnWwY4Tpc44hSXO|YYm= NGfjT2QyOMLiwsXN NVrIXI5IOjRiaB?= NUTrNWdscW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC= NVj1eZdlOjZ2MEe2OVM>
SGC-7901/DDP M37MSWZ2dmO2aX;uJGF{e2G7 MX6xNOKhyrWP NYSz[HBPOjRiaB?= MlKxZ4F2e2W|IHGgcYFzc2WmIHTlZ5Jm[XOnIHnuJJRp\SCuZY\lcEBw\iCEY3ytNkBxem:2ZXnu NGnDVWMzPjRyN{[1Ny=>
H357 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX23MlUwOTBizszN M4HiZlQ5KGh? M4jyNGROW09? MkfEbY5pcWKrdIOgZ4VtdCCpcn;3eIjDqGOxbXLpcoVlKHerdHigV4FjfXSxY3zhfC=> MY[yOlAxQTh5NB?=
TAF M{PpSmZ2dmO2aX;uJGF{e2G7 Mlf0NVDDqML3TR?= NHXnPY04KGR? NYnKZnFW[W[oZXP0d{BVSU[|IHHkbIV{cX[nIIDyc5BmenSrZYO= MXOyOVk5PzF{Nx?=
TAF NF\kVWFHfW6ldHnvckBCe3OjeR?= NIH2d48yOMLiwsXN MV6zNE0yOjBibXnu NHq4b4lxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc> M2nDNVI2QTh5MUK3
TAF NXz1fmk{TnWwY4Tpc44hSXO|YYm= M4jyVVExyqEEtV2= NFnxS4o1QCCq MkTibY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MVKyOVk5PzF{Nx?=
PANC-1 NV;kSVRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2yNE83OC9zMECg{txO MljPNlQwPDhxN{KgbC=> Mn;HbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MmXaNlU6PzNyNkK=
PANC-1 NUPO[I9rTnWwY4Tpc44hSXO|YYm= MmLvNlAwPjBxMUCwJO69VQ>? M{LxeVI1KGh? M4LEWYF1fGWwdXH0d{Bk\WyuIHnueoF{cW:wIHHu[EBucWe{YYTpc44hcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NX7WRZZUOjV7N{OwOlI>
HeLa  MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q2NFIxyqEQvF5CpC=> M{nK[FI1yqCq MYflcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MkLyNlU4PzB2MkO=
SACC-83 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTv[|hkOjEEoN88UeKh M2XiclI1yqCq NGnPXpJmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= M4js[|I2PzdyNEKz
HeLa  NX;iR4pbSXCxcITvd4l{KEG|c3H5 NVTtNXB5OjEEoN88UeKh NIT1XJQzPMLiaB?= M1zsUYVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> NHGzV4kzPTd5MESyNy=>
SACC-83 NICxb21CeG:ydH;zbZMhSXO|YYm= NUHsWG5SOjEEoN88UeKh MojHNlTDqGh? MVflcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz M2LUOFI2PzdyNEKz
HeLa  M1fxWGZ2dmO2aX;uJGF{e2G7 NX\q[o9sOjBxNECvPFAh|ryP MXyyOOKhcA>? MYr1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> MXWyOVc4ODR{Mx?=
SACC-83 MUjGeY5kfGmxbjDBd5NigQ>? MnPtNlAwPDBxOECg{txO MUOyOOKhcA>? M1XKTZVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV NXfYZXVLOjV5N{C0NlM>
HLCZ01 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKw5qCUPjEEoNM1US=> NXXNeIJHPDhiaB?= M13ldWROW09? M3\YcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M4rqN|I2PzJ2OEm5
HLCZ01 MVvGeY5kfGmxbjDBd5NigQ>? MVu0NOKh|ryP NIm5V4czPCCq M2D5PWROW09? MWHpcoNz\WG|ZYOgZYNkfW23bHH0bY9vKG:oIFewM2cyNXCqYYPlJINmdGy|IHPvcYJqdmWmIIfpeIghUU[QLd8x MUSyOVczPDh7OR?=
HLCZ01 NHu0UmlCeG:ydH;zbZMhSXO|YYm= MWK0NOKh|ryP NIiwbGYzPCCq NGfKXJBFVVOR NFHxPYVmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u|rF? NVi5cpBxOjV5MkS4PVk>
HLCZ01 MYXGeY5kfGmxbjDBd5NigQ>? M3\xZlQxyqEQvF2= NXvWeWNUOjRiaB?= NGXUTXFFVVOR MUfpcoNz\WG|ZYOgWHJCUUxiZYjwdoV{e2mxbjDjc41jcW6nZDD3bZRpKEmwdHXy[oVzd25vzsG= NUXEdmQ5OjV5MkS4PVk>
MGC803 NXH1TpNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrLcpVWOC14MDFOwG0> MYK3NkBp M1;MS2lEPTB;NEeuNlXjiIoEsfMAjVYvPDNizszN MX:yOVcxOTN5OB?=
SGC7901 NIXxZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSwZ2xEOC14MDFOwG0> NHfBeWY4OiCq MVvJR|UxRTR|LkWz5qCKyrIkgJm1MlEzKM7:TR?= MoKwNlU4ODF|N{i=
MGC803 NGDpdGZHfW6ldHnvckBCe3OjeR?= M4fRdFQxyqEQvF2= NXy3fFdoQC9zNj:yOEBp M{e4[JVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> NX3kVG43OjV5MEGzO|g>
SGC7901 MkfzSpVv[3Srb36gRZN{[Xl? NWHITGszPDEEoN88US=> MU[4M|E3NzJ2IHi= MX;1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= NEfESFgzPTdyMUO3PC=>
MCF-7  M13aOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfqNWJvOS9zMDFOwG0> MYm3NkBp NIr5OHRFVVOR NX3sNIhN\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= Mn3NNlU3Pjd3MUC=
MDA-MB-231  Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXyxM|ExKM7:TR?= NVTMZndbPzJiaB?= NXHEdI9tTE2VTx?= NEOwSlhmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= M2fHfFI2PjZ5NUGw
MDA-MB-231 NGjySo1HfW6ldHnvckBCe3OjeR?= MnKxNE01OCEEtV2= NGjMcnI1NTJ2IHi= MlvtbY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M1nQXlI2PTh5M{K5
MCF-7 MmnVSpVv[3Srb36gRZN{[Xl? M3PlSlAuPDBiwsXN NYnjUGlLPC1{NDDo MoC2[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? MWOyOVU5PzN{OR?=
MCF7-MX  MnjnSpVv[3Srb36gRZN{[Xl? M4DRdFAuPDBiwsXN MkHUOE0zPCCq NWjBcHI4\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?= Mny0NlU2QDd|Mkm=
MDA-MB-231 MoHoSpVv[3Srb36gRZN{[Xl? MX6wMVQxKML3TR?= NUnwcII6PC1{NDDo NXP4WmFQe3SrbYXsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCDQlPHNkB2eCC2bzC0MlI4KHSrbXXzJJRwKGOxboTyc4whdGW4ZXygZpkhOTJiaNMg M1XOWlI2PTh5M{K5
A2780 NUDFeXVtTnWwY4Tpc44hSXO|YYm= M4TGTlUwOTBxMUWg{txO M2TzS|Q5KGh? NYHie5V3\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVeyOVQzPDh7OB?=
SKOV3  NHnNZ3RHfW6ldHnvckBCe3OjeR?= NIT4SIU2NzFyL{G1JO69VQ>? MljIOFghcA>? NWexUHNq\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEXsbngzPTR{NEi5PC=>
A2780 M4XibmZ2dmO2aX;uJGF{e2G7 MnHCOU8yOC9zNTFOwG0> NW\H[4ZtPDhiaB?= NGfmfIFmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw NXXWbHZCOjV2MkS4PVg>
SKOV3  MmXvSpVv[3Srb36gRZN{[Xl? NVTZU|EyPS9zMD:xOUDPxE1? NXnG[pB4PDhiaB?= NHL0WodmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw M1nKOVI2PDJ2OEm4
A2780 MWLGeY5kfGmxbjDBd5NigQ>? MkC4OU8yOC9zNTFOwG0> MkP1OFghcA>? NIDTZ5dl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= MmXTNlU1OjR6OUi=
SKOV3  NUTPWlBkTnWwY4Tpc44hSXO|YYm= MojzOU8yOC9zNTFOwG0> NV3wbHpqPDhiaB?= M2LG[oRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= NXq1WFJWOjV2MkS4PVg>
A2780 Mo\USpVv[3Srb36gRZN{[Xl? MnG2OU8yOC9zNTFOwG0> NVjm[3JROSCq MojhbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUDTbYM6OjV2MkS4PVg>
SKOV3  MnvKSpVv[3Srb36gRZN{[Xl? MlmxOU8yOC9zNTFOwG0> M3;RNlEhcA>? MofZbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYmyOVQzPDh7OB?=
HCT-15 MUXGeY5kfGmxbjDBd5NigQ>? MX:xNE02OCEQvF2= MlX5Ok0{PiCq NUnOZo1ocW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NYrkRoJsOjV{MUiwNlg>
HT-29  Mlz0SpVv[3Srb36gRZN{[Xl? M2LU[VExNTVyIN88US=> MUW2MVM3KGh? MmP5bY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= MmTkNlUzOThyMki=
HSC3  NXPVd4M5S2WubDDWbYFjcWyrdImgRZN{[Xl? NUDBbItkOOLCk{SwJO69VQ>? MUi0PEBp MWLJR|UxRTJ3LkZCtVEvPzhyIN88US=> NXrXOGtZOjVzOUi3PFk>
HSC3  NWD0cJFRSXCxcITvd4l{KEG|c3H5 NFfMfVMzPSEQvF2= MnrYOFghcA>? MmLSbY5lfWOnczDhdI9xfG:|aYO= MXGyOVE6QDd6OR?=
HSC3  NIL2TmxHfW6ldHnvckBCe3OjeR?= MWiyOUDPxE1? MX20PEBp M1LxToV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR? NVvmc3p1OjVzOUi3PFk>
HSC3  NV[zcmZJTnWwY4Tpc44hSXO|YYm= NX7QOmhsOjVizszN NUTCUVZUPDhiaB?= NULQSG55cW6qaXLpeJMhUFOFMzDj[YxtKGmwdnHzbY9vKGOxbXLpcoVlKHerdHigR2VV NF3zXlQzPTF7OEe4PS=>
HSC3  NETrS5VHfW6ldHnvckBCe3OjeR?= MV:yOUDPxE1? Ml34O|IhcA>? MXzk[YNz\WG|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6|wrC= MnrDNlUyQTh5OEm=
201T  NX\z[WpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXG3NkBp M3jCdmROW09? NGjESYxKSzVyPUS4MlYhyrWP NELLU3ozPTB3N{m0NS=>
273T MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrlb5A4OiCq M{XRVWROW09? MorhTWM2OD16MD61JOK2VQ>? MlXZNlUxPTd7NEG=
Hep-2 NInKfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrnZ3I{OC93MD:xNFAh|ryP NX7DU|RnOTJxMkSvN|YwPDhiaB?= NXjR[4pvTE2VTx?= NHe3fYxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{\JNlI1QTl6NU[0
Hep-2 MW\BdI9xfG:|aYOgRZN{[Xl? MmLzOVAh|ryP M1y5W|AuPDhiaB?= NX\oc|JUTE2VTx?= M{fOcIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy NUHPNYt1OjR7OUi1OlQ>
Hep-2 NWnsdnRRTnWwY4Tpc44hSXO|YYm= MmOwOVAh|ryP MnTMNE01QCCq MUXEUXNQ M4DSVpJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 M2LVXFI1QTl6NU[0
Hep-2 M1rDWGZ2dmO2aX;uJGF{e2G7 Mm\zOVAh|ryP NF3wV2IxNTR6IHi= Ml;KSG1UVw>? NWXESIhy\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? MXOyOFk6QDV4NB?=
SGC-7901 NW\lNYxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37tOlExNzVyL{GwNEDPxE1? M33FOFI1NzR6L{eyJIg> MUXEUXNQ NUO5Z|kzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MWSyOFk6Ojl3OB?=
MKN-45 NE\UVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTFdotwOTBxNUCvNVAxKM7:TR?= NGrNbGgzPC92OD:3NkBp NFTrXnlFVVOR MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1vMXlI1QTl{OUW4
SGC-7901 NUTmT|Y2TnWwY4Tpc44hSXO|YYm= NWmyNpM3OTBxNUCvNVAxKM7:TR?= MlHkOFghcA>? MoKxSG1UVw>? NHK1[m5ld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MoGzNlQ6QTJ7NUi=
MKN-45 NHLqZ5dHfW6ldHnvckBCe3OjeR?= MXuxNE82OC9zMECg{txO MUi0PEBp MljDSG1UVw>? Mkjv[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NGrmcGkzPDl7Mkm1PC=>
C666-1 MVHDfZRwfG:6aXPpeJkhSXO|YYm= NFnHR|MzOC16MDFOwG0> NEPQNnkzPCCq NGnieIZl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh MWGyOFg2PDh|OB?=
CNE-1 Mo\aR5l1d3SxeHnjbZR6KEG|c3H5 MlLCNlAuQDBizszN Mo\4NlQhcA>? NXrHUFZR\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MlS2NlQ5PTR6M{i=
CNE-2 M37Bd2N6fG:2b4jpZ4l1gSCDc4PhfS=> NHizVHAzOC16MDFOwG0> M4jNflI1KGh? MoHp[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> MlPtNlQ5PTR6M{i=
C666-1 NYPVe5RDS3m2b4TvfIlkcXS7IFHzd4F6 NV7KRllZPjBizszN NYrOUIV5PyCm M4TGVYVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy NGjSPWEzPDh3NEizPC=>
CNE-1 NFziWYZEgXSxdH;4bYNqfHliQYPzZZk> M1HNflYxKM7:TR?= MWK3JIQ> NVrrS457\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> M2H6cVI1QDV2OEO4
SNU-1041 M1ToXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPHVHBROC12MDFOwG0> MUe0PEBp MVLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M4jw[VI1Pjl{N{Cz
SNU-1041 M4W5NmZ2dmO2aX;uJGF{e2G7 MUiyNE8{OCEQvF2= MlLpOEBp NVniWVB7cW6mdXPld{BmgHC{ZYPzbY9vKG:owrDDTG9RNCCJUmC3POKh[W6mwrDYRnAyyqCjdDD0bIUhWk6DIHzleoVtyqB? NH\BPI8zPDZ7MkewNy=>
SNU-1041 MlHqSpVv[3Srb36gRZN{[Xl? Mmm5NE01OCEQvF2= M4fLZlQhcA>? NYDrRZlYfXBvcnXneYxifGW|IFPIU3DDqGGodHXyJJRz\WG2bXXueEB4cXSqIHjp[4gh[2:wY3XueJJifGmxboO= M3LtUlI1Pjl{N{Cz
SGC-7901 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi1NE0yOjVizszN M1ToWVI1NzR6L{eyJIg> MkmxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUDBfGtrOjR4N{[zPVQ>
SGC-7901 NHTle3RCeG:ydH;zbZMhSXO|YYm= M1vZe|ExOCEQvF2= MUG3NkBp MV\pcoR2[2W|IHHwc5B1d3Orcx?= M1fSbFI1Pjd4M{m0
SGC-7901 M1fR[GZ2dmO2aX;uJGF{e2G7 NEDB[Vk4PS9zMECvNVI2KM7:TR?= NHnsXYEzPC92OD:3NkBp NWDKWYJUcW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> MUiyOFY4PjN7NB?=
LMeC  Ml3tSpVv[3Srb36gRZN{[Xl? M{LZVFIxNzVyIN88US=> NInPfXo1QCCq NGqx[I9l\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?= Mn7INlQ3PTZ5NE[=
CMeC-1 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYHQUG9rOjBxNUCg{txO NFfjXlE1QCCq MUHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M4KxWFI1PjV4N{S2
LMeC M1vhV2NmdGxiVnnhZoltcXS7IFHzd4F6 NInrTIYzOC93MDFOwG0> M4XtOVQ5KGh? NILDeZdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXvvR2h1OjR4NU[3OFY>
CMeC-1 MYDGeY5kfGmxbjDBd5NigQ>? MVuyNE82OCEQvF2= MWG0PEBp NUnafoU1cW6mdXPld{BIOS2VIHHydoV{fA>? NIH6OmEzPDZ3Nke0Oi=>
LMeC Ml7QSpVv[3Srb36gRZN{[Xl? MWOyNE82OCEQvF2= Ml;MOFghcA>? M2ribolv\HWlZYOgS|EuWyCjcoLld5Q> NUXuPFZZOjR4NU[3OFY>
CMeC-1 NVTaOmRKTnWwY4Tpc44hSXO|YYm= NHzkeWszOC93MDFOwG0> MYq0PEBp M33vTIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoTlNlQ3PTZ5NE[=
LMeC MYPGeY5kfGmxbjDBd5NigQ>? MnvGNlAwPTBizszN MVy0PEBp MnL0[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEHCOoUzPDZ3Nke0Oi=>
CMeC-1 NH3ldpZHfW6ldHnvckBCe3OjeR?= NF\VTVkzOC93MDFOwG0> NHrvXIY1QCCq M3yzd4lv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> MljPNlQ3PTZ5NE[=
LMeC NF;lcoRHfW6ldHnvckBCe3OjeR?= NG\teFQzOC93MDFOwG0> NUPOSlJjPDhiaB?= MYDpcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u MoH4NlQ3PTZ5NE[=
OVCAR-3 NH76UWxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGjWVnQyOCEEtV2= NYf5cItSOSCq NWrPZWM{\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? MoLxNlQ2OjB{Mke=
OVCAR-3 MWXBdI9xfG:|aYOgRZN{[Xl? MYOxNEDDvU1? MXyxJIg> NHX4WnRxem:vb4Tld{Bx[WOuaYThfIVtNWmwZIXj[YQh[XCxcITvd4l{yqB? M{XDbFI1PTJyMkK3
OVCAR-3 MlHWSpVv[3Srb36gRZN{[Xl? MWSxNEDDvU1? MVSxJIg> MlHP[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S17wrC= M{nEZlI1PTJyMkK3
OVCAR-3 M1\E[WZ2dmO2aX;uJGF{e2G7 NVrVVYYyOTBiwsXN NWThU4lKOSCq NY\CeYlF\G:5bj3y[Yd2dGG2ZYOgUmYu|rqEIHHjeIl3[XSrb36gbY5lfWOnZDDifUBx[WOuaYThfIVt NHvsW4EzPDV{MEKyOy=>
OVCAR-3 NEm3OlNHfW6ldHnvckBCe3OjeR?= NWHNdnA6OTBiwsXN MmTnNUBp MmjNbY5pcWKrdIOgdIFkdGm2YYjlcE1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> MX2yOFUzODJ{Nx?=
CF33 NXPCRVlRTnWwY4Tpc44hSXO|YYm= MVOxNFAh|ryP NGHWXGwzPCCq MmnqbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDDU3guOiCycn;0[YlvKGW6cILld5Nqd25? NYXaR2hFOjR3MEO3PFI>
CF33 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fGblExNTFyMDFOwG0> M{HqTFAuPCCm NITTV29qdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXWyOFUxOzd6Mh?=
CF33 Mn3HSpVv[3Srb36gRZN{[Xl? M4jUelExNTFyMDFOwG0> M{DUWFQuOjRiaB?= Mm\S[IVkemWjc3XzJINmdGy|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG|ZYOgZ4VtdHNiaX6gS|AwTzFiYYLy[ZN1 Ml\VNlQ2ODN5OEK=
LNCaP MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOyM|UwOTBizszN MnvXPVYhcA>? NXHibZpDcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NYXOSpdKOjR{OU[5O|g>
LNCaP MnraRZBweHSxc3nzJGF{e2G7 NVzyd4lsOi93L{GwJO69VQ>? MorEPVYhcA>? MojlbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= MWWyOFI6Pjl5OB?=
PC-3  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMVUxKM7:TR?= M1:3cFQ56oDLaB?= M{XPN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NV;IXI57OjRzMke4PFI>
PC-3  Mkm5R4VtdCCYaXHibYxqfHliQYPzZZk> NFPafoQxNTFyMDFOwG0> NYLUWodZPzJiaB?= MVPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NELJUGszPDF{N{i4Ni=>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03590821 Not yet recruiting Healthy University of Pennsylvania November 2019 Early Phase 1
NCT03590821 Not yet recruiting Healthy University of Pennsylvania November 2019 Early Phase 1
NCT03864575 Not yet recruiting Metastatic Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain April 15 2019 Phase 2
NCT03864575 Not yet recruiting Metastatic Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain April 15 2019 Phase 2
NCT01344200 Not yet recruiting Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT03850587 Not yet recruiting Osteoarthritis Knee Yooyoung Pharmaceutical Co. Ltd.|Green Cross Corporation March 3 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products4

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID